登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002584 证券简称：西陇科学 公告编号：2026-006 二、与会计师事务所沟通情况 本次业绩预告未经注册会计师审计。公司就本次业绩预告有关事项与会计师事务所进行了预沟通，公司 与会计师事务所在业绩预告方面不存在重大分歧，具体数据请以最终审计结果为准。 三、业绩变动原因说明 2025年度归属于上市公司股东的净利润同比上期下降且为负，主要原因系报告期内，根据2021年12月7 日公司与济南高新实业发展有限公司（已更名为"济南高新生物科技有限公司"）、济南高新财金投资有 限公司、济南高新盛和发展有限公司签订的《山东艾克韦生物技术有限公司股权转让协议》，约定的标 的公司艾克韦生物2022年度-2024年度经审计后的业绩承诺未完成，公司就该次股权转让承担的业绩补 偿款在本报告期计提预计负债11,503.44万元，导致本报告期归属于上市公司股东的净利润为负。 四、其他相关说明 本次业绩预告是公司财务部门初步测算的结果，具体财务数据以公司披露的 2025年年度报告为准。敬 请广大投资者谨慎决策，注意投资风险。 本公司及董事会全体成员保证信息披露的内容真实、准 ...

南财智讯1月30日电，西陇科学发布2025年度业绩预告，预计2025年全年归属于上市公司股东的净利润 为亏损4000万元—7000万元；预计2025年全年归属于上市公司股东的扣除非经常性损益的净利润为盈利 4800万元—7200万元，同比预减3.59%—35.73%。2025年度归属于上市公司股东的净利润同比上期下降 且为负，主要原因系报告期内，根据2021年12月7日公司与济南高新实业发展有限公司（已更名为"济南 高新生物科技有限公司"）、济南高新财金投资有限公司、济南高新盛和发展有限公司签订的《山东艾 克韦生物技术有限公司股权转让协议》，约定的标的公司艾克韦生物2022年度-2024年度经审计后的业 绩承诺未完成，公司就该次股权转让承担的业绩补偿款在本报告期计提预计负债11503.44万元，导致本 期归属于上市公司股东的净利润为负。 ...

证券代码：002584 证券简称：西陇科学 公告编号：2026-006 西陇科学股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日 | 2、业绩预告情况：预计净利润为负值 | | --- | | 项 | 目 | | 本报告期 | | 上年同期 | | | --- | --- | --- | --- | --- | --- | --- | | 归属于上市公司股 东的净利润 | | 亏损：4,000 | 万元–7,000 | 万元 | 盈利：6,177.34 | 万元 | | 扣除非经常性损益 后的净利润 | | 盈利：4,800 | 万元–7,200 | 万元 | 盈利：7,468.06 | 万元 | | | | | 比上年同期下降：35.73% | - 3.59% | | | | 基本每股收益 | | 亏损：0.07 | 元/股–0.12 | 元/股 | 盈利：0.11 元/股 | | 二、与会计师事务所沟通情况 本次业绩 ...

格隆汇1月28日丨西陇科学(002584.SZ)在互动平台表示，公司主要从事化学试剂的研发、生产、销售， 原料药及食品添加剂生产及销售，并从事部分化工原料贸易等业务。公司部分电子化学品、硝酸银、银 粉等产品可用于光伏领域。 ...

Group 1 - The core issue involves Xilong Science Co., Ltd. being penalized for inflating revenue and profits through fictitious trading activities in ethylene glycol and methanol during the years 2020 and 2021, as revealed by the China Securities Regulatory Commission [1] - The company has been fined and responsible individuals have been held accountable for their actions, which were disclosed in a correction announcement on April 29, 2023 [1] - A final ruling by the Guangdong High People's Court confirmed that the company must compensate 82 investors for losses amounting to over 7.57 million yuan, indicating judicial support for investor claims [1] Group 2 - The conditions for compensation state that investors who purchased Xilong Science stock between April 29, 2021, and April 29, 2023, and either sold or continued to hold the stock after April 29, 2023, are eligible for claims [2] - Required documentation for claims includes original transaction statements stamped by the brokerage, copies of the investor's ID, a confirmation of the securities account from the brokerage, and the investor's contact information [2] Group 3 - The lawyer, Niu Bin, indicated that the compensation registration conditions are based on existing judicial decisions and interpretations, and the final conditions will be determined by the court [3]

受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我 2023年7月7日，西陇科学（维权）股份有限公司公告收到中国证券监督管理委员会广东监管局下发的 《行政处罚决定书》（[2023]16号）。经查明，西陇科学为扩大贸易规模、提升市场影响力及获取融资 便利，通过虚构乙二醇、甲醇等贸易业务，在2020年、2021年年度报告以及2022年半年度报告中虚增营 业收入与利润。公司因此被处以罚款，相关责任人也被追究责任。 该虚假陈述行为于2023年4月29日，随公司发布《前期会计差错更正公告》而被揭露。2025年11月10 日，公司发布公告称，广东省高级人民法院已作出终审裁定，此前汕头市中级人民法院一审判决公司向 82名投资者赔偿损失757万余元的判决正式生效。这表明投资者的索赔诉求已获得司法支持。 （本文由上海百悦律师事务所牛彬律师供稿。牛彬律师，已执业24年，擅长代理证券诉讼、金融维权案 件，有多年投资者维权诉讼经验。） 上海百悦律师事务所牛彬律师表示，根据《证 ...

Group 1 - The core point of the article is that Xilong Science Co., Ltd. has won a procurement project from Sinopec Catalyst Co., Ltd. with a bid amount of 1.792 million yuan for iron nitrate [1] Group 2 - Xilong Science (002584.SZ) reported a revenue of 7.816 billion yuan in 2024, with a revenue growth rate of 10.22% and a net profit attributable to the parent company of 62 million yuan, reflecting a net profit growth rate of 85.24% [2] - In the first half of 2025, the company reported a revenue of 3.368 billion yuan, with a revenue growth rate of -14.78% and a net profit attributable to the parent company of -75 million yuan, indicating a net profit growth rate of -276.35% [3] - The company operates in the materials industry, primarily dealing with inorganic chemical raw materials, with its 2024 revenue composition being 56.48% specialized chemicals, 22.63% chemical raw materials, 11.81% electronic chemicals, 7.92% general reagents, 0.68% raw materials for pharmaceuticals and food additives, 0.31% lithium battery cathode materials, and 0.16% other businesses [3]

Market Performance - The recombinant protein sector declined by 0.62%, ranking among the top losers in the concept sectors, with *ST WanFang hitting the daily limit down [1] - Notable declines in the sector included Aladdin, Zexing Pharmaceutical, and Shutaishen, while 18 stocks within the sector saw price increases, with Haitai Biological, Yabao Pharmaceutical, and Zhongyuan Qihe leading with gains of 4.28%, 1.17%, and 1.08% respectively [1] Capital Flow - The recombinant protein sector experienced a net outflow of 479 million yuan, with 41 stocks seeing net outflows, and 6 stocks with outflows exceeding 30 million yuan [1] - The stock with the highest net outflow was Xilong Science, with a net outflow of 59.20 million yuan, followed by Aladdin, Shutaishen, and Aimeike with outflows of 50.46 million yuan, 39.78 million yuan, and 39.10 million yuan respectively [1] Top Gainers and Losers - The top gainers in the recombinant protein sector included Haitai Biological, with a gain of 4.28%, and the top losers included Aladdin and Shutaishen, with declines of 6.46% and 2.49% respectively [1][2] - Other notable stocks with significant capital inflows included Haitai Biological, Huayu Pharmaceutical, and Tonghua Dongbao, with net inflows of 17.77 million yuan, 15.97 million yuan, and 9.97 million yuan respectively [3]

Core Viewpoint - The articles discuss ongoing investor compensation cases against companies Xilong Science and Puli Pharmaceutical due to false financial disclosures, highlighting the legal actions taken by investors and the financial discrepancies identified by regulatory authorities [1][2][4][5]. Group 1: Xilong Science - Xilong Science has faced legal actions due to false statements leading to investor compensation claims, with a recent case submitted to the Shantou Intermediate People's Court [1][4]. - The company was found to have inflated its financial figures significantly, with 2020 showing inflated revenue of approximately 597.65 million yuan, costs of about 595.99 million yuan, and profits of around 1.66 million yuan, representing 9.57%, 10.34%, and 2.04% of total revenue, costs, and profits respectively [1][4]. - For 2021, the inflated revenue was approximately 1.46 billion yuan, costs around 1.44 billion yuan, and profits about 13.48 million yuan, accounting for 21.32%, 22.98%, and 5.93% of total revenue, costs, and profits respectively [1][4]. Group 2: Puli Pharmaceutical - Puli Pharmaceutical is also facing investor compensation claims, with a recent case submitted to the Haikou Intermediate People's Court, where investors have won a preliminary judgment [2][5]. - The company was found to have overstated its revenue by approximately 514.60 million yuan in 2021, which constituted 34.11% of the reported revenue, and inflated profits by about 308.02 million yuan, making up 65.88% of the total profit [2][5]. - In 2022, the company overstated its revenue by approximately 515.90 million yuan, representing 28.56% of the reported revenue, and inflated profits by about 387.42 million yuan, which was 88.27% of the total profit [2][5]. Group 3: Legal Context - Investors who purchased shares of Puli Pharmaceutical between April 26, 2022, and April 17, 2024, or shares of Xilong Science between April 29, 2021, and April 29, 2023, are eligible to initiate compensation claims [3][6]. - The legal actions are being led by attorney Xu Feng from Shanghai Jucheng Law Firm, who has extensive experience in securities fraud cases [3][6].

Group 1 - The law firm Shanghai Jiucheng is representing investors in lawsuits against Xilong Science and Puli Pharmaceutical for false statements leading to financial losses [1][2] - Xilong Science was found to have inflated its revenue by approximately 597.65 million yuan in 2020, 1.46 billion yuan in 2021, and 785.35 million yuan in the first half of 2022, affecting its reported profits significantly [1] - Puli Pharmaceutical reported inflated revenues of about 514.60 million yuan in 2021 and 515.90 million yuan in 2022, with corresponding profit overstatements of 308.02 million yuan and 387.42 million yuan, respectively [2] Group 2 - Investors who purchased Puli Pharmaceutical shares between April 26, 2022, and April 17, 2024, or Xilong Science shares between April 29, 2021, and April 29, 2023, may still initiate claims for compensation [3] - The law firm has a history of successfully representing investors in similar cases, having handled nearly 200 cases resulting in victories or settlements [3]